NCT06849947 2025-12-24Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast CancerSamsung Medical CenterPhase 2 Not yet recruiting272 enrolled